These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 28239934)

  • 1. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.
    Uchida Y; Kouyama JI; Naiki K; Sugawara K; Inao M; Imai Y; Nakayama N; Mochida S
    Hepatol Res; 2017 Dec; 47(13):1397-1407. PubMed ID: 28239934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.
    Uchida Y; Kouyama JI; Naiki K; Sugawara K; Inao M; Imai Y; Nakayama N; Mochida S
    Hepatol Res; 2016 Nov; 46(12):1234-1246. PubMed ID: 26878268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b.
    Honda K; Seike M; Oribe J; Endo M; Arakawa M; Tokoro M; Iwao M; Mori T; Nishimura J; Takahashi Y; Omori K; Yamashita T; Muro T; Murakami K
    Hepatol Res; 2018 Mar; 48(4):255-263. PubMed ID: 29080280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection.
    Miura M; Maekawa S; Sato M; Komatsu N; Tatsumi A; Takano S; Amemiya F; Nakayama Y; Inoue T; Sakamoto M; Enomoto N
    Hepatol Res; 2014 Dec; 44(14):E360-7. PubMed ID: 24612030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Ishikawa T; Tachi Y; Hattori M; Katano Y; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2018 Jan; 33(1):249-255. PubMed ID: 28440885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay.
    Yoshimi S; Ochi H; Murakami E; Uchida T; Kan H; Akamatsu S; Hayes CN; Abe H; Miki D; Hiraga N; Imamura M; Aikata H; Chayama K
    PLoS One; 2015; 10(6):e0130022. PubMed ID: 26083687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.
    Uemura H; Uchida Y; Kouyama JI; Naiki K; Yamaba S; Fuchigami A; Saito Y; Shiokawa K; Fujii Y; Uchiya H; Nakazawa M; Ando S; Nakao M; Motoya D; Sugawara K; Inao M; Imai Y; Nakayama N; Tomiya T; Mochida S
    Hepatol Res; 2018 Mar; 48(4):233-243. PubMed ID: 28884930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
    J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms.
    Knops E; Sierra S; Kalaghatgi P; Heger E; Kaiser R; Kalinina OV
    Genes (Basel); 2018 Jul; 9(7):. PubMed ID: 29986475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.
    Kurata H; Uchida Y; Kouyama JI; Naiki K; Nakazawa M; Ando S; Nakao M; Motoya D; Sugawara K; Inao M; Imai Y; Nakayama N; Tomiya T; Mochida S
    Hepatol Res; 2018 Feb; 48(3):E372-E378. PubMed ID: 28872737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.
    Uchida Y; Kouyama J; Naiki K; Mochida S
    PLoS One; 2014; 9(11):e112647. PubMed ID: 25397971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
    Iio E; Shimada N; Takaguchi K; Senoh T; Eguchi Y; Atsukawa M; Tsubota A; Abe H; Kato K; Kusakabe A; Miyaki T; Matsuura K; Matsunami K; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    Hepatol Res; 2017 Nov; 47(12):1308-1316. PubMed ID: 28332272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
    Kai Y; Hikita H; Morishita N; Murai K; Nakabori T; Iio S; Hagiwara H; Imai Y; Tamura S; Tsutsui S; Naito M; Nishiuchi M; Kondo Y; Kato T; Suemizu H; Yamada R; Oze T; Yakushijin T; Hiramatsu N; Sakamori R; Tatsumi T; Takehara T
    Sci Rep; 2017 Jan; 7():41660. PubMed ID: 28134353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
    Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
    Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.
    Ide T; Eguchi Y; Harada M; Ishii K; Morita M; Morita Y; Sugiyama G; Fukushima H; Yano Y; Noguchi K; Nakamura H; Hisatomi J; Kumemura H; Shirachi M; Iwane S; Okada M; Honma Y; Arinaga-Hino T; Miyajima I; Ogata K; Kuwahara R; Amano K; Kawaguchi T; Kuromatsu R; Torimura T;
    PLoS One; 2016; 11(9):e0163884. PubMed ID: 27684567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants.
    Okubo T; Atsukawa M; Tsubota A; Shimada N; Abe H; Yoshizawa K; Arai T; Nakagawa A; Itokawa N; Kondo C; Aizawa Y; Iwakiri K
    Hepatol Res; 2017 Jun; 47(7):641-649. PubMed ID: 27487797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
    Wang Y; Rao HY; Xie XW; Wei L
    Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.